2023

  • Nyman J, Denize T, Bakouny Z, Labaki C, Titchen BM, Bi K, Hari SN, Rosenthal J, Mehta N, Jiang B, Sharma B, Felt K, Umeton R, Braun DA, Rodig S, Choueiri TK, Signoretti S, Van Allen EM. Spatially aware deep learning reveals tumor heterogeneity patterns that encode distinct kidney cancer states. Cell Rep Med. 2023 Sep 19;4(9):101189. doi: 10.1016/j.xcrm.2023.101189. PMID: 37729872; PMCID: PMC10518628.

  • Henske EP, Cheng L, Hakimi AA, Choueiri TK, Braun DA. Chromophobe renal cell sup. Cancer Cell. 2023 Aug 14;41(8):1383-1388. doi: 10.1016/j.ccell.2023.07.006. PMID: 37541245.

  • Schindler NR, Braun DA. Antigenic targets in clear cell renal cell carcinoma. Kidney Cancer. 2023 Aug 11;7(1):81–91. doi: 10.3233/KCA-230006. PMCID: PMC10475986.

  • Schoenfeld DA, Moutafi M, Martinez S, Djureinovic D, Merkin RD, Adeniran A, Braun DA, Signoretti S, Choueiri TK, Parisi F, Hurwitz M, Rimm DL, Wei W, Jilaveanu L, Kluger HM. Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases. J Immunother Cancer. 2023 Aug;11(8):e007240. doi: 10.1136/jitc-2023-007240. PMID: 37586773; PMCID: PMC10432651.

  • Labaki C, Saliby RM, Bakouny Z, Saad E, Semaan K, Eid M, Lalani AK*, Choueiri TK*, Braun DA*. Emerging Biomarkers of Response to Systemic Therapies in Metastatic Clear Cell Renal Cell Carcinoma. Hematol Oncol Clin North Am. 2023 Jul 3:S0889-8588(23)00076-X. doi: 10.1016/j.hoc.2023.05.021. PMID: 37407357.

  • Anderson KG, Braun DA, Buqué A, Gitto SB, Guerriero JL, Horton B, Keenan BP, Kim TS, Overacre-Delgoffe A, Ruella M, Triplett TA, Veeranki O, Verma V, Zhang F. Leveraging immune resistance archetypes in solid cancer to inform next-generation anticancer therapies. J Immunother Cancer. 2023 Jun;11(6):e006533. doi: 10.1136/jitc-2022-006533. PMID: 37399356; PMCID: PMC10314654.

  • Saad E, Saliby RM, Labaki C, Xu W, Viswanathan SR, Braun DA*, Bakouny Z*. Novel Immune Therapies for Renal Cell Carcinoma: Looking Beyond the Programmed Cell Death Protein 1 and Cytotoxic T-Lymphocyte-Associated Protein 4 Axes. Hematol Oncol Clin North Am. 2023 Jun 28:S0889-8588(23)00078-3. doi: 10.1016/j.hoc.2023.05.023. PMID: 37391289.

  • Saliby RM, Saad E, Labaki C, Xu W, Braun DA, Viswanathan SR, Bakouny Z. Novel Targeted Therapies for Renal Cell Carcinoma: Building on the Successes of Vascular Endothelial Growth Factor and mTOR Inhibition. Hematol Oncol Clin North Am. 2023 Jun 27:S0889-8588(23)00077-1. doi: 10.1016/j.hoc.2023.05.022. PMID: 37385938.

  • Saliby RM, El Zarif T, Bakouny Z, Shah V, Xie W, Flippot R, Denize T, Kane MH, Madsen KN, Ficial M, Hirsch L, Wei XX, Steinarter JA, Harshman LC, Vaishampayan UN, Severgnini M, McDermott DF, Lee GM, Xu W, Van Allen EM, McGregor BA, Signoretti S, Choueiri TK, McKay RR*, Braun DA*. Circulating and intratumoral immune determinants of response to atezolizumab plus bevacizumab in patients with variant histology or sarcomatoid renal cell carcinoma. Cancer Immunol Res. 2023 Jun 6:CIR-22-0996. doi: 10.1158/2326-6066.CIR-22-0996. PMID: 37279009.

  • Braun DA, Chakraborty AA. Immunobiology and Metabolic Pathways of Renal Cell Carcinoma. Hematol Oncol Clin North Am. 2023 May 26:S0889-8588(23)00046-1. doi: 10.1016/j.hoc.2023.04.012. PMID: 37246090.

  • Kashima S, Braun DA. The Changing Landscape of Immunotherapy for Advanced Renal Cancer. Urol Clin North Am. 2023 May;50(2):335-349. doi: 10.1016/j.ucl.2023.01.012. Epub 2023 Feb 20. PMID: 36948676.

  • Atkins MB, Jegede OA, Haas NB, McDermott DF, Bilen MA, Stein M, Sosman JA, Alter R, Plimack ER, Ornstein MC, Hurwitz M, Peace DJ, Signoretti S, Denize T, Cimadamore A, Wu CJ, Braun D, Einstein D, Catalano PJ, Hammers H. Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B). J Immunother Cancer. 2023 Mar;11(3):e004780. doi: 10.1136/jitc-2022-004780. PMID: 36948504.

  • Nassar AH, Abou Alaiwi S, Baca SC, Adib E, Corona RI, Seo JH, Fonseca MAS, Spisak S, El Zarif T, Tisza V, Braun DA, Du H, He M, Flaifel A, Alchoueiry M, Denize T, Matar SG, Acosta A, Shukla S, Hou Y, Steinharter J, Bouchard G, Berchuck JE, O'Connor E, Bell C, Nuzzo PV, Mary Lee GS, Signoretti S, Hirsch MS, Pomerantz M, Henske E, Gusev A, Lawrenson K, Choueiri TK, Kwiatkowski DJ, Freedman ML. Epigenomic charting and functional annotation of risk loci in renal cell carcinoma. Nat Commun. 2023 Jan 21;14(1):346. doi: 10.1038/s41467-023-35833-5. PMID: 36681680.

2022

  • Groha S, Alaiwi SA, Xu W, Naranbhai V, Nassar AH, Bakouny Z, El Zarif T, Saliby RM, Wan G, Rajeh A, Adib E, Nuzzo PV, Schmidt AL, Labaki C, Ricciuti B, Alessi JV, Braun DA, Shukla SA, Keenan TE, Van Allen E, Awad MM, Manos M, Rahma O, Zubiri L, Villani AC, Fairfax B, Hammer C, Khan Z, Reynolds K, Semenov Y, Schrag D, Kehl KL, Freedman ML, Choueiri TK, Gusev A. Germline variants associated with toxicity to immune checkpoint blockade. Nat Med. 2022 Dec 16. doi: 10.1038/s41591-022-02094-6. PMID: 36526723

  • Liu S, Iorgulescu JB, Li S, Borji M, Barrera-Lopez IA, Shanmugam V, Lyu H, Morriss JW, Garcia ZN, Murray E, Reardon D, Yoon CH, Braun DA, Livak KJ, Wu CJ, Chen F. Spatial maps of T cell receptors and transcriptomes reveal distinct immune niches and interactions in the adaptive immune response”. Immunity, 2022 Oct 11..

  • Denize T, Hou Y, Pignon JC, Walton E, West DJ, Freeman GJ, Braun DA, Wu CJ, Gupta S, Motzer RJ, Atkins MB, McDermott D, Choueiri TK, Shukla SA, Signoretti S. Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma. Clin Cancer Res. 2022 Jul 8. PMID: 35802667.

  • Oliveira G, Stromhaug K, Cieri N, Iorgulescu JB, Klaeger S, Wolff JO, Rachimi S, Chea V, Krause K, Freeman SS, Zhang W, Li S, Braun DA, Neuberg D, Carr SA, Livak KJ, Frederick DT, Fritsch EF, Wind-Rotolo M, Hacohen N, Sade-Feldman M, Yoon CH, Keskin DB, Ott PA, Rodig SJ, Boland GM, Wu CJ. Landscape of helper and regulatory antitumour CD4+ T cells in melanoma. Nature. 2022 May 4. PMID: 35508657.

  • Atkins M, Jegede OA, Haas NB, McDermott DF, Bilen MA, Stein M, Sosman JA, Alter R, Plimack ER, Ornstein M, Hurwitz M, Peace DJ, Signoretti S, Denize T, Cimadamore A, Wu CJ, Braun DA, Einstein D, Catalano PJ, Hammers H. Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients with advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A).  J Clin Oncol. 2022 Apr 20. PMID: 35442713.

  • Braun DA and Wu CJ. Tumor-Infiltrating T Cells — A Portrait. N Engl J Med. 2022 Mar 10. PMID: 35263526

  • Denize T, Farah S, Cimadamore A, Faifel A, Walton E, Sticco-Ivins MA, Labaki C, Braun DA, Sun M, Wang E, Xie W, Choueiri TK, Signoretti S. Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial. Clin Cancer Res. 2022 Jan 10. doi: 10.1158/1078-0432.CCR-21-3088. PMID: 34921022.

  • Bakouny, Z, Sadagopan, A, Ravi, P, Metaferia, NY, Li, J, AbuHammad, S, Tang, S, Denize, T, Garner, ER, Gao, X, Braun, DA, Hirsch, L, Steinharter, JA, Bouchard, G, Walton, E, West, D, Labaki, C, Dudani, S, Gan, C-L, Sethunath, V, Carvalho, FLF, Imamovic, A, Ricker, C, Vokes, NI, Nyman, J, Berchuck, JE, Park, J, Hirsch, MS, Haq, R, Mary Lee, G-S, McGregor, BA, Chang, SL, Feldman, AS, Wu, CJ, McDermott, DF, Heng, DYC, Signoretti, S, Van Allen, EM, Choueiri, TK, and Viswanathan, SR. Integrative clinical and molecular characterization of translocation renal cell carcinoma. Cell Rep. 2022 Jan 04. PMID: 34986355.

2021

  • Choueiri TK, Albiges L, Atkins MB, Bakouny Z, Bratslavsky G, Braun DA, Haas NB, Haanen JBAG, Hakimi AA, Jewett MAS, Jonasch E, Kaelin WG, Kapur P, Labaki C, Lewis B, McDermott DF, Pal SK, Pels K, Poteat S, Powles T, Rathmell WK, Rini BI, Signoretti S, Tannir NM, Uzzo RG, Hammers HJ. From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit. Clin Cancer Res. 2021 Dec 29. PMID: 34965942.

  • Naranbhai V, Viard M, Dean M, Groha S, Braun DA, Labaki C, Shukla SA, Yuki Y, Shah P, Chin K, Wind-Rotolo M, Mu XJ, Robbins PB, Gusev A, Choueiri TK, Gulley JL, Carrington M. HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study. Lancet Oncol. 2021 Dec 09. PMID: 34895481.

  • Hirsch L, Martinez Chanza N, Farah S, Xie W, Flippot R, Braun DA, Rathi N, Thouvenin J, Collier KA, Seront E, de Velasco G, Dzimitrowicz H, Beuselinck B, Xu W, Bowman IA, Lam ET, Abuqayas B, Bilen MA, Varkaris A, Zakharia Y, Harrison MR, Mortazavi A, Barthélémy P, Agarwal N, McKay RR, Brastianos PK, Krajewski KM, Albigès L, Harshman LC, Choueiri TK. Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma. JAMA Oncol. 2021 Oct 21. PMID: 34673916.

  • Bakouny Z, Yekedüz E, Braun DA, Berchuck JE, Hirsch L, Utkan G, Lee Y, Trinh QD, Choueiri TK, Ürün Y. Neurotoxicities of Novel Non-Steroidal Anti-Androgens for Prostate Cancer: A Systematic Review and Meta-Analysis. Crit Rev Oncol Hematol. 2021 Aug 27; 103463. PMID: 34461269.

  • Klaeger S, Apffel A, Clauser KR, Sarkizova S, Oliveira G, Rachimi S, Le PM, Tarren A, Chea V, Abelin JG, Braun DA, Ott PA, Keshishian H, Hacohen N, Keskin DB, Wu CJ, Carr SA. Optimized liquid and gas phase fractionation increases HLA-peptidome coverage for primary cell and tissue samples. Mol Cell Proteomics. 2021 Aug 12; 100133. PMID: 34391888.

  • Yang ES, Nassar AH, Adib E, Jegede OA, Abou Alaiwi S, Della Manna DL, Braun DA, Zarei M, Du H, Pal SK, Naik G, Sonpavde GP. Gene expression signature correlates with outcomes in metastatic renal cell carcinoma patients treated with everolimus alone or with a vascular disrupting agent. Mol Cancer Ther. 2021 Jun 09. PMID: 34108261.

  • Adib E, Nassar AH, Akl EW, Abou Alaiwi S, Nuzzo PV, Mouhieddine TH, Sonpavde G, Haddad RI, Mouw KW, Giannakis M, Hodi FS, Shukla SA, Gusev A, Braun DA, Choueiri TK, Kwiatkowski DJ. CDKN2A Alterations and Response to Immunotherapy in Solid Tumors. Clin Cancer Res. 2021 Jun 01. PMID: 34074656.

  • Braun DA*, Street K*, Burke KP, Cookmeyer DL, Denize T, Pedersen CB, Gohil SH, Schindler N, Pomerance L, Hirsch L, Bakouny Z, Hou Y, Forman J, Huang T, Li S, Cui A, Keskin DB, Steinharter J, Bouchard G, Sun M, Pimenta EM, Xu W, Mahoney KM, McGregor BA, Hirsch MS, Chang SL, Livak KJ, McDermott DF, Shukla SA, Olsen LR, Signoretti S, Sharpe AH, Irizarry RA, Choueiri TK, Wu CJ. Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. Cancer Cell. 2021 Mar 09. PMID: 33711273.

    This work was featured on the Cancer Cell Cover (May 2021), in a Cancer Cell Preview article (https://doi.org/10.1016/j.ccell.2021.03.008), and in a Nature Reviews Urology Research Highlight article (https://doi.org/10.1038/s41585-021-00471-3).

 
 

  • Bi K, He MX, Bakouny Z, Kanodia A, Napolitano S, Wu J, Grimaldi G, Braun DA, Cuoco MS, Mayorga A, DelloStritto L, Bouchard G, Steinharter J, Tewari AK, Vokes NI, Shannon E, Sun M, Park J, Chang SL, McGregor BA, Haq R, Denize T, Signoretti S, Guerriero JL, Vigneau S, Rozenblatt-Rosen O, Rotem A, Regev A, Choueiri TK, Van Allen EM. Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma. Cancer Cell. 2021 Mar 10. PMID: 33711272.

  • Bakouny Z, Braun DA, Shukla SA, Pan W, Gao X, Hou Y, Flaifel A, Tang S, Bosma-Moody A, He MX, Vokes N, Nyman J, Xie W, Nassar AH, Abou Alaiwi S, Flippot R, Bouchard G, Steinharter JA, Nuzzo PV, Ficial M, Sant'Angelo M, Forman J, Berchuck JE, Dudani S, Bi K, Park J, Camp S, Sticco-Ivins M, Hirsch L, Baca SC, Wind-Rotolo M, Ross-Macdonald P, Sun M, Lee GM, Chang SL, Wei XX, McGregor BA, Harshman LC, Genovese G, Ellis L, Pomerantz M, Hirsch MS, Freedman ML, Atkins MB, Wu CJ, Ho TH, Linehan WM, McDermott DF, Heng DYC, Viswanathan SR, Signoretti S, Van Allen EM, Choueiri TK. Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. Nat Commun. 2021 02 05; 12(1):808. PMID: 33547292.

  • Braun DA*, Bakouny Z*, Hirsch L, Flippot R, Van Allen EM, Wu CJ, Choueiri TK. Beyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinoma. Nat Rev Clin Oncol. 2021 Jan 12. PMID: 33437048.

2020

  • Gohil SH*, Iorgulescu JB*, Braun DA*, Keskin DB, Livak KJ. Applying high-dimensional single-cell technologies to the analysis of cancer immunotherapy. Nat Rev Clin Oncol. 2020 Dec 04. PMID: 33277626.

  • Ficial M, Jegede OA, Sant'Angelo M, Hou Y, Flaifel A, Pignon JC, Braun DA, Wind-Rotolo M, Sticco-Ivins M, Catalano PJ, Freeman GJ, Sharpe AH, Hodi FS, Motzer RJ, Wu CJ, Atkins MB, McDermott DF, Shukla SA, Choueiri TK, Signoretti S. Expression of T-cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma. Clin Cancer Res. 2020 Nov 20. PMID: 33219016.

  • McKay RR, McGregor BA, Xie W, Braun DA, Wei X, Kyriakopoulos CE, Zakharia Y, Maughan BL, Rose TL, Stadler WM, McDermott DF, Harshman LC, Choueiri TK. Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE). J Clin Oncol. 2020 Oct 27; JCO2002295. PMID: 33108238.

  • McGregor BA, Lalani AA, Xie W, Steinharter JA, E Bakouny Z, Martini DJ, Fleischer JH, Abou-Alaiwi S, Nassar A, Nuzzo PV, Kaymakcalan MD, Braun DA, Wei XX, Harshman LC, Bilen MA, Choueiri TK. Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma. Eur J Cancer. 2020 Aug; 135:203-210. PMID: 32599410.

  • Braun DA, Hou Y, Bakouny Z, Ficial M, Sant' Angelo M, Forman J, Ross-Macdonald P, Berger AC, Jegede OA, Elagina L, Steinharter J, Sun M, Wind-Rotolo M, Pignon JC, Cherniack AD, Lichtenstein L, Neuberg D, Catalano P, Freeman GJ, Sharpe AH, McDermott DF, Van Allen EM, Signoretti S, Wu CJ, Shukla SA, Choueiri TK. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nat Med. 2020 Jun; 26(6):909-918. PMID: 32472114.

 

  • Lasseter K, Nassar AH, Hamieh L, Berchuck JE, Nuzzo PV, Korthauer K, Shinagare AB, Ogorek B, McKay R, Thorner AR, Lee GM, Braun DA, Bhatt RS, Freedman M, Choueiri TK, Kwiatkowski DJ. Plasma cell-free DNA variant analysis compared with methylated DNA analysis in renal cell carcinoma. Genet Med. 2020 Apr 28. PMID: 32341571.

  • Abou Alaiwi S, Nassar AH, Xie W, Bakouny Z, Berchuck JE, Braun DA, Baca SC, Nuzzo PV, Flippot R, Mouhieddine TH, Spurr LF, Li YY, Li T, Flaifel A, Steinharter JA, Margolis CA, Vokes NI, Du H, Shukla SA, Cherniack AD, Sonpavde G, Haddad RI, Awad MM, Giannakis M, Hodi FS, Liu XS, Signoretti S, Kadoch C, Freedman ML, Kwiatkowski DJ, Van Allen EM, Choueiri TK. Mammalian SWI/SNF complex genomic alterations and immune checkpoint blockade in solid tumors. Cancer Immunol Res. 2020 Apr 22. PMID: 32321774.

2019

  • Sarkizova S, Klaeger S, Le PM, Li LW, Oliveira G, Keshishian H, Hartigan CR, Zhang W, Braun DA, Ligon KL, Bachireddy P, Zervantonakis IK, Rosenbluth JM, Ouspenskaia T, Law T, Justesen S, Stevens J, Lane WJ, Eisenhaure T, Lan Zhang G, Clauser KR, Hacohen N, Carr SA, Wu CJ, Keskin DB. A large peptidome dataset improves HLA class I epitope prediction across most of the human population. Nat Biotechnol. 2019 Dec 16. PMID: 31844290.

  • Hollenhorst MA, Braun DA, Burtner CR, Cajigas I, Cunningham-Bussel AC, Eser PÖ, Nabel CS, Tsai FD, Weeks LD, Michel T, Yialamas MA. Bridging the Divide: Student Grand Rounds at the Interface of Basic Science and Clinical Medicine. Acad Med. 2019 Dec 10. PMID: 31833852.

  • McGregor BA, McKay RR, Braun DA, Werner L, Gray K, Flaifel A, Signoretti S, Hirsch MS, Steinharter JA, Bakouny Z, Flippot R, Wei XX, Choudhury A, Kilbridge K, Freeman GJ, Van Allen EM, Harshman LC, McDermott DF, Vaishampayan U, Choueiri TK. Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features. J Clin Oncol. 2019 Nov 13; JCO1901882. PMID: 31721643.

  • Li H, Bullock K, Gurjao C, Braun D, Shukla SA, Bossé D, Lalani AA, Gopal S, Jin C, Horak C, Wind-Rotolo M, Signoretti S, McDermott DF, Freeman GJ, Van Allen EM, Schreiber SL, Stephen Hodi F, Sellers WR, Garraway LA, Clish CB, Choueiri TK, Giannakis M. Metabolomic adaptations and correlates of survival to immune checkpoint blockade. Nat Commun. 2019 Sep 25; 10(1):4346. PMID: 31554815. PMCID: PMC6761178.

  • Lalani AA, Xie W, Braun DA, Kaymakcalan M, Bossé D, Steinharter JA, Martini DJ, Simantov R, Lin X, Wei XX, McGregor BA, McKay RR, Harshman LC, Choueiri TK. Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma. Eur Urol Oncol. 2019 Sep 24. PMID: 31562048.

  • Braun DA, Ishii Y, Walsh AM, Van Allen EM, Wu CJ, Shukla SA, Choueiri TK. Clinical Validation of PBRM1 Alterations as a Marker of Immune Checkpoint Inhibitor Response in Renal Cell Carcinoma. JAMA Oncol. 2019 Sep 05. PMID: 31486842; PMCID: PMC6735411.

  • Flaifel A, Xie W, Braun DA, Ficial M, Bakouny Z, Nassar AH, Jennings RB, Escudier B, George DJ, Motzer RJ, Morris MJ, Powles T, Wang E, Huang Y, Freeman GJ, Choueiri TK, Signoretti S. PD-L1 expression and clinical outcomes to cabozantinib, everolimus and sunitinib in patients with metastatic renal cell carcinoma: analysis of the randomized clinical trials METEOR and CABOSUN. Clin Cancer Res. 2019 Aug 01. PMID: 31371341.

  • Braun DA, Henderson GV, Sax PE, Miller AL, Loscalzo J. A Disturbing Decline. N Engl J Med. 2019 Jun 06; 380(23):2257-62. PMID: 31167056.

  • Braun DA, Simchowitz B, Henderson GV, Sax PE, Vaidya A. A Disturbing Decline. N Engl J Med. 2019 May 30; 380(22):e42. PMID: 31141638.

  • Pignon JC, Jegede O, Shukla SA, Braun DA, Horak CE, Wind-Rotolo M, Ishii Y, Catalano PJ, Grosha J, Flaifel A, Novak JS, Mahoney KM, Freeman GJ, Sharpe AH, Hodi FS, Motzer RJ, Choueiri TK, Wu CJ, Atkins MB, McDermott DF, Signoretti S. irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial. Clin Cancer Res. 2019 Apr 01;25(7):2174-84. PMID: 30670497; PMCID: PMC6445699.

  • Bakouny Z, Flippot R, Braun DA, Lalani AA, Choueiri TK. State of the Future: Translational Approaches in Renal Cell Carcinoma in the Immunotherapy Era. Eur Urol Focus. 2019 Feb 28. pii: S2405-4569(19)30049-5. PMID: 30827939.

  • Varshney A, Braun DA, Patel AB, Yialamas MA. What was old is new again: learning from the modern master clinician. Clin Teach. 2019 Jun; 16(3):274-6. PMID: 30125460.

2018

  • Iorgulescu JB, Braun D, Oliveira G, Keskin DB, Wu CJ. Acquired mechanisms of immune escape in cancer following immunotherapy. Genome Med. 2018 11 22;10(1):87. PMID: 30466478. PMCID: PMC6249768.

  • DeFilippis EM, Vaidya A, Braun D, Lakdawala N, Sobieszczyk P. A Shocking Turn of Events. N Engl J Med. 2018 May 24; 378(21):e29. PMID: 29791827.

  • McKay RR, Bossé D, Xie W, Wankowicz SAM, Flaifel A, Brandao R, Lalani AA, Martini DJ, Wei XX, Braun DA, Van Allen E, Castellano D, De Velasco G, Wells JC, Heng DY, Fay AP, Schutz FA, Hsu J, Pal SK, Lee JL, Hsieh JJ, Harshman LC, Signoretti S, Motzer RJ, Feldman D, Choueiri TK. The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma. Cancer Immunol Res. 2018 07;6(7):758-65. PMID: 29748390; PMCID: PMC6712567.

  • Richterman A, Vaidya A, Brown JM, Braun DA, Samuels MA. In the Balance. N Engl J Med. 2018 Jan 18;378(3):e5. PMID: 29342378.

2017

  • Alonso CD, Braun DA, Patel I, Akbari M, Oh DJ, Jun T, McMasters M, Hammond SP, Glotzbecker B, Cutler C, Leffler D, Ballen KK, Kelly CP. A multicenter, retrospective, case-cohort study of the epidemiology and risk factors for Clostridium difficile infection among cord blood transplant recipients. Transpl Infect Dis. 2017 Aug;19(4). doi: 10.1111/tid.12728; PMID: 28544102.

  • Braun DA, Wu CJ. Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies. Cancer J. 2017 Mar/Apr;23(2):115-24. PMID: 28410299; PMCID: PMC5856170.

  • Braun DA, Burke KP, Van Allen EM. Genomic Approaches to Understanding Response and Resistance to Immunotherapy. Clin Cancer Res. 2016 Dec 01;22(23):5642-50. PMID: 27698000;PMCID: PMC5135569.

2016

  • Laitman BM, Asp L, Mariani JN, Zhang J, Liu J, Sawai S, Chapouly C, Horng S, Kramer EG, Mitiku N, Loo H, Burlant N, Pedre X, Hara Y, Nudelman G, Zaslavsky E, Lee YM, Braun DA, Lu QR, Narla G, Raine CS, Friedman SL, Casaccia P, John GR. The Transcriptional Activator Krüppel-like Factor-6 Is Required for CNS Myelination. PLoS Biol. 2016 May; 14(5):e1002467. PMID: 27213272; PMCID: PMC4877075.

2013

  • Braun DA, Fribourg M, Sealfon SC. Cytokine response is determined by duration of receptor and signal transducers and activators of transcription 3 (STAT3) activation. J Biol Chem. 2013 Feb 1; 288(5):2986-93. PMID: 23166328; PMCID: PMC3561523.

2011

  • Zhang J, Zhang Y, Dutta DJ, Argaw AT, Bonnamain V, Seto J, Braun DA, Zameer A, Hayot F, Lòpez CB, Raine CS, John GR. Proapoptotic and antiapoptotic actions of Stat1 versus Stat3 underlie neuroprotective and immunoregulatory functions of IL-11. J Immunol. 2011 Aug 1; 187(3):1129-41. PMID: 21709156; PMCID: PMC31643.

2005

  • Braun, D, Basu, S, Weiss, R. IEEE International Conference on Acoustics, Speech, and Signal Processing, Proceedings. Parameter estimation for two synthetic gene networks: a case study. 2005; 5:v/769 - v/772.